Literature DB >> 17152145

Ocular complications of childhood rheumatic diseases: uveitis.

Andreas Reiff1.   

Abstract

Ocular involvement is common in pediatric rheumatologic diseases, supporting the concept that these conditions cannot be understood simply as isolated entities, but rather as multisystem disorders. The reasons for the breach of the eye-brain barrier and the targeting of the usually well-shielded eye during a pan-inflammatory process remains unclear. Pediatric rheumatologists should become familiar with these ocular disorders, because as important members of the treatment team, they manage more serious cases of inflammatory eye disease. A close collaboration between the treating rheumatologist and the ophthalmologist is essential to prevent potentially devastating outcomes. Therapeutic interventions such as topical steroids, systemic immunosuppressants, and biologics must balance the necessity of controlling ocular inflammation and the adverse effects of these treatments on a growing child.

Entities:  

Mesh:

Year:  2006        PMID: 17152145     DOI: 10.1007/s11926-006-0042-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  103 in total

Review 1.  Uveitis associated with juvenile idiopathic arthritis: envisioning the future.

Authors:  Allan M Rosenberg
Journal:  J Rheumatol       Date:  2002-11       Impact factor: 4.666

2.  Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration.

Authors:  Wee-Kiak Lim; Chiaki Fujimoto; Roxana Ursea; Sankaranarayana Pillai Mahesh; Phyllis Silver; Chi-Chao Chan; Igal Gery; Robert B Nussenblatt
Journal:  Arch Ophthalmol       Date:  2005-07

3.  Etanercept therapy in children with treatment-resistant uveitis.

Authors:  A Reiff; S Takei; S Sadeghi; A Stout; B Shaham; B Bernstein; K Gallagher; T Stout
Journal:  Arthritis Rheum       Date:  2001-06

Review 4.  Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.

Authors:  Robert S Wallis; Stefan Ehlers
Journal:  Semin Arthritis Rheum       Date:  2005-04       Impact factor: 5.532

5.  Molecular analysis of resolving immune responses in uveitis.

Authors:  P I Murray; C D Clay; C Mappin; M Salmon
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

6.  Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.

Authors:  Robert B Nussenblatt; Jan S Peterson; C Stephen Foster; Narsing A Rao; Robert F See; Eric Letko; Ronald R Buggage
Journal:  Ophthalmology       Date:  2005-05       Impact factor: 12.079

7.  Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization.

Authors:  S A Vinores; C C Chan; M A Vinores; D M Matteson; Y S Chen; D A Klein; A Shi; H Ozaki; P A Campochiaro
Journal:  J Neuroimmunol       Date:  1998-08-14       Impact factor: 3.478

8.  Clinical analysis of 40 cases of childhood-onset Behçet's disease.

Authors:  D K Kim; S N Chang; D Bang; E S Lee; S Lee
Journal:  Pediatr Dermatol       Date:  1994-06       Impact factor: 1.588

9.  The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27.

Authors:  A Linssen; A Rothova; H A Valkenburg; A J Dekker-Saeys; L Luyendijk; A Kijlstra; T E Feltkamp
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-08       Impact factor: 4.799

10.  The ocular manifestations of juvenile rheumatoid arthritis.

Authors:  L T Chylack
Journal:  Arthritis Rheum       Date:  1977-03
View more
  5 in total

Review 1.  The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.

Authors:  Melissa A Lerman; C Egla Rabinovich
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

Review 2.  Ocular complications of childhood rheumatic diseases: nonuveitic inflammatory eye diseases.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

Review 3.  Intraocular inflammation: its causes and investigations.

Authors:  Claire Hooper; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.919

4.  High dose infliximab in the treatment of refractory uveitis: does dose matter?

Authors:  Sukesh Sukumaran; Katherine Marzan; Bracha Shaham; Andreas Reiff
Journal:  ISRN Rheumatol       Date:  2012-01-05

Review 5.  Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.

Authors:  Katherine Anne B Marzan
Journal:  Adolesc Health Med Ther       Date:  2012-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.